Compare Salesforce Inc (CRM) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs Crispr Therapeutics AG — how do they compare? Salesforce Inc trades at $229.13 (market cap $187.48B), while Crispr Therapeutics AG trades at $53.39 (market cap $4.88B). The key difference: Salesforce Inc is far larger — about 38.4× Crispr Therapeutics AG's market cap, and Salesforce Inc pays a 0.77% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Salesforce Inc for 89 Days and Crispr Therapeutics AG for 77 Days on average.
| CRM | CRSP | |
|---|---|---|
Market Cap | $187.48B | $4.88B |
Volume | 6,155,822 | 2,861,747 |
Sector | Technology | Health |
52-Week High | $266.23 | $73.97 |
52-Week Low | $150.12 | $44.34 |
Typical Hold Time | 89 Days | 77 Days |
Enterprise Value | $217.82B | $3.30B |
Dividend Yield | 0.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $227.80, up 1.44% with strong fundamentals including 77.28% gross margins and consistent earnings beats. The stock shows bearish technical signals but maintains robust revenue growth trajectory from $37.9B in 2025 to projected $43.9B in 2026. Recent AI-driven innovations like Agentforce and Data 360 show promising monetization potential with $2.9B ARR growth.
Despite technical headwinds, Salesforce presents compelling value with 76.5% analyst buy ratings and $271.91 price target representing 19% upside. Key risks include AI competition pressure and software sector volatility, but strong cash flow generation and market leadership support long-term growth prospects.
CRISPR Therapeutics (CRSP) trades at $50.44, down 3.65% on the day, reflecting a bearish technical trend amid weak financials. The company reported no revenue in 2025, with a net loss of $581.60M and negative profit margins, though it beat Q2 2026 EPS estimates. Analyst consensus remains bullish with a $67.83 price target, while recent news highlights upcoming clinical data readouts for its gene-editing therapies as potential catalysts.
The outlook hinges on pipeline execution, with key data expected by end-2026, but high cash burn and lack of revenue pose significant risks. Upside depends on successful clinical outcomes and commercialization of CASGEVY, while downside risks include trial failures and sustained losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
